Asthma

New Class Of Drugs Shows Promise In Tackling Multifactorial Diseases

Published in Gene Therapy Weekly, June 14th, 2001

Research presented by scientists from EpiGenesis of Cranbury, New Jersey, indicates a new class of drugs may offer improved control of multifactorial diseases by targeting multiple mRNAs simultaneously.

The class of drugs being studied is respirable antisense oligonucleotides (RASONs), pioneered by EpiGenesis. Multifactorial diseases include asthma, chronic obstructive pulmonary diseases, and many cancers.

The data were presented at the "Antisense 2001, Advances in EpiGenetic Medicine" international conference, sponsored by the scientific publication, Nature Biotechnology.

"We have found occurrences of near total...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry